EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study

Giuseppe Lapadula, Luca Mezzadri, Giustina Lo Cascio, Laura Antolini, Sergio Malandrin, Alice Ranzani, Silvia Limonta, Annalisa Cavallero, Paolo Bonfanti

Infection · 2024

DOI: 10.1007/s15010-024-02250-9 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Infection, 2024. Verfasst von Giuseppe Lapadula und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. giuseppe.lapadula@unimib.it. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Viral, SARS-CoV-2, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Milano - Bicocca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Antibodies against SARS-CoV-2 spike (anti-S) may confer protection against symptomatic COVID-19. Whether their level predicts progression among those with COVID-19 pneumonia remains unclear.

Methods

We conducted a retrospective cohort study to assess predictors of anti-S levels and whether anti-S titer is associated with death or mechanical ventilation (MV). Adults hospitalized for COVID-19 pneumonia between July 2021 and July 2022 were enrolled if anti-S had been measured within 72 h of admission. Predictors of anti-S level were explored using multivariable quantile regression. The association between anti-S levels and 30-day death/MV was investigated via multivariable logistic regression. Analyses were stratified by vaccine status.

Results

The median anti-S level was 1370 BAU/ml in 328 vaccinated and 15.5 BAU/ml in 206 unvaccinated individuals. Among the vaccinated, shorter symptom duration ( p = 0.001), hematological malignancies ( p = 0.002), and immunosuppressive therapy ( p = 0.004) were associated with lower anti-S levels. In the unvaccinated group, symptom duration was the only predictor of anti-S levels ( p < 0.001). After 30 days, 134 patients experienced death or MV. Among vaccinated individuals, higher anti-S levels correlated significantly with lower death/MV risk (per log 2 increase, OR 0.88, 95%CI 0.81–0.97), irrespective of age and solid malignancies. Among unvaccinated, a marginally protective effect was observed (OR 0.86, 95%CI 0.73–1.01), independent of age, immunosuppressive therapy, and diabetes. Adjustment for monoclonal antibody treatment strengthened the association (OR 0.81, 95%CI 0.68–0.96).

Conclusion

This study suggests that levels of anti-S antibodies can predict critical or fatal outcomes in COVID-19 pneumonia patients, regardless of vaccination. Whether anti-S Ab could guide risk assessment and vaccination boosting merits further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, ViralSARS-CoV-2Spike Glycoprotein, CoronavirusDisease ProgressionHumansRetrospective StudiesMaleFemaleMiddle AgedAgedHospitalizationRespiration, ArtificialAdultCOVID-19 VaccinesCohort Studies

Stichwörter der Autor:innen

Anti-Spike antibody levelCOVID-19 pneumoniaClinical progressionSARS-CoV-2Vaccination

Substanzen

Antibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19 Vaccines

Autor:innen und Institutionen

  • Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. giuseppe.lapadula@unimib.it.
  • School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. giuseppe.lapadula@unimib.it.
  • School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  • Bicocca Bioinformatics Biostatistics and Bioimaging Center-B4, University of Milano-Bicocca, Milan, Italy.
  • Microbiology Unit, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
  • Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.

Förderung

  • Università degli Studi di Milano - Bicocca

Zitieren

APA

Lapadula, G., Mezzadri, L., Lo Cascio, G., Antolini, L., Malandrin, S., Ranzani, A., Limonta, S., Cavallero, A., & Bonfanti, P. (2024). Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study. Infection. https://doi.org/10.1007/s15010-024-02250-9

Vancouver

Lapadula G, Mezzadri L, Lo Cascio G, Antolini L, Malandrin S, Ranzani A, et al. Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study. Infection. 2024. doi:10.1007/s15010-024-02250-9

BibTeX
@article{Lapadula2024,
  author = {Lapadula, Giuseppe and Mezzadri, Luca and Lo Cascio, Giustina and Antolini, Laura and Malandrin, Sergio and Ranzani, Alice and Limonta, Silvia and Cavallero, Annalisa and Bonfanti, Paolo},
  title = {Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study},
  journal = {Infection},
  year = {2024},
  doi = {10.1007/s15010-024-02250-9}
}
Kostenlos starten →